Skip to main content
SpringerLink
Log in

Effectiveness and safety of Glargine U-100 and detemir insulin in hyperglycemic pregnancy: a record-based observational study

  • Original Article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Background

Gestational diabetes mellitus (GDM), a common medical condition affecting a high number of pregnant women worldwide, is characterized by high blood glucose levels that develop during pregnancy, usually in the second or third trimester, in women with no prior history of diabetes. While GDM usually resolves after delivery, it can have significant short-term and long-term adverse effects on both the mother and the fetus. Though insulin therapy is the recommended primary treatment, there exists limited evidence comparing the safety and effectiveness of different long-acting insulin analogues, including glargine U-100 and detemir insulin.

Objective

The study aimed to compare the effectiveness and safety of long-acting insulin analogs, glargine U-100 and detemir insulin, in hyperglycemic pregnancy.

Methods

This record-based observational study involved 64 subjects, with data collected from medical records. The study assessed demographic data, glycaemic parameters, incidence of hypoglycemia, and neonatal outcomes.

Results

The results showed that both insulins were effective in reducing glycaemic levels, but glargine U-100 was associated with better glycemic control, fewer hypoglycemic episodes and less need for dose intensification. The results showed that both insulins were safe when considering infants’ health assessed at 6 months.

Conclusion

The study concluded that glargine U-100 may be a preferred treatment option for hyperglycemic pregnancy. Further studies are needed for optimizing treatment strategies in hyperglycemic pregnancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data Availability

Data supporting the finding of this study are available within the article text and tables.

References

  1. Callesen NF, Damm J, Mathiesen JM, Ringholm L, Damm P, Mathiesen ER. Treatment with the long-acting insulin analogues detemir or glargine during pregnancy in women with type 1 diabetes: comparison of glycemic control and pregnancy outcome. J Matern Fetal Neonatal Med. 2013;26(6):588–92.

    Article  CAS  PubMed  Google Scholar 

  2. Metzger BE, Gabbe SG, Persson B, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33(3):676–82.

    Article  PubMed  Google Scholar 

  3. Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005;115(5):485–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fernandez A, Landon MB. Gestational diabetes mellitus: metabolic and cardiovascular implications. Semin Perinatol. 2002;26(2):137–43.

    Google Scholar 

  5. Landon MB. The management of the pregnant patient with diabetes. Obstet Gynecol. 2003;102(1):167–78.

    Google Scholar 

  6. Coustan DR. Diabetes in pregnancy. Clin Obstet Gynecol. 1997;40(3):495–502.

    Google Scholar 

  7. Ferrer RL, Sussman JB, Zaslavsky AM, et al. Rates of detection of hyperglycemia and diabetes following gestational diabetes mellitus among Mexican and Nicaraguan women. Diabetes Educ. 2013;39(4):478–87.

    Google Scholar 

  8. American Diabetes Association. 14. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(Suppl 1):S165–72.

    Article  Google Scholar 

  9. Poon K, King AB. Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs. Drug Healthc Patient Saf. 2010;2:213–23. https://doi.org/10.2147/DHPS.S7301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Stewart ZA, Wilinska ME, Hartnell S, et al. Closed-loop insulin delivery during pregnancy in women with type 1 diabetes. N Engl J Med. 2016;375(5):644–54.

    Article  CAS  PubMed  Google Scholar 

  11. Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med. 2000;343(24):1134–8.

    Article  CAS  PubMed  Google Scholar 

  12. Buschur EO, Sood A, Himes KP, et al. The safety and efficacy of insulin detemir in pregnancy: a systematic review. J Womens Health (Larchmt). 2015;24(4):305–13.

    Google Scholar 

  13. Recommendations from SEC. Accessed at https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/Recommendations%20Endocrinology%20&%20Metabolism%2019.01.2023%20&%2020.01.2023.pdf. Accessed 1 May 2023

  14. Damm P, Mathiesen ER. The role of insulin analogues in the treatment of diabetes during pregnancy. Diabetologia. 2008;51(11):2099–102.

    Google Scholar 

  15. Blum AK. Insulin Use in Pregnancy: An Update. Diabetes Spectr. 2016;29(2):92–7. https://doi.org/10.2337/diaspect.29.2.92.Erratum.In:DiabetesSpectr.2016Aug;29(3):191.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008;31(4):1060–79.

    Article  CAS  PubMed  Google Scholar 

  17. Diabetes UK. Diabetes in Pregnancy: Management from Preconception to the Postnatal Period. Recommendations and Audit Standards. 2010. Available from: https://www.diabetes.org.uk/professionals/position-statements-reports/pregnancy-position-statement-2010. Accessed 1 May 2023

  18. Pollex E, Lubetsky A, Koren G. The fetal safety of insulin glargine. Diabetes Obes Metab. 2010;12(9):794–801. https://doi.org/10.1111/j.1463-1326.2010.01217.x.

    Article  Google Scholar 

  19. Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932–8. https://doi.org/10.4103/ijo.IJO_1627_21.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

No funding was received for this research.

Author information

Authors and Affiliations

  1. Diabetes & Allergy-Asthma Therapeutics Specialty Clinic, Kolkata, West Bengal, India

    Shambo S. Samajdar

  2. Department of Clinical Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India

    Shambo S. Samajdar, Shatavisa Mukherjee, Sougata Sarkar & Satyabrata Sahoo

  3. Joshi Clinic, Mumbai, India

    Shashank R. Joshi

  4. Department of Pharmacology, Netaji Subhas Medical College & Hospital, Patna, Bihar, India

    Santanu K. Tripathi

  5. Department of General Medicine, SSKM Hospital & IPGMER, Kolkata, West Bengal, India

    Nandini Chatterjee

  6. Department of General Medicine, Sagar Dutta Medical College & Hospital, Kolkata, West Bengal, India

    Jyotirmoy Pal

  7. AHC Diabetes Clinic, Arogyam Health Care, Ahmedabad, Gujarat, India

    Rutul A. Gokalani

Authors
  1. Shambo S. Samajdar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shashank R. Joshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shatavisa Mukherjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sougata Sarkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Santanu K. Tripathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Satyabrata Sahoo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Nandini Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jyotirmoy Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Rutul A. Gokalani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SSS & SRJ conceptualized the study. SSS, SS, SKT, JP, NC, SS, RT had done the literature study. SSS, SRJ, SKT, JP, NC, SM, RT had been involved in data extraction and analysis. SSS, SS, SM, SS, NC, JP, RT had been involved in manuscript preparation and editing. All authors have read and approved the final version of this manuscript. Requirements for authorship as stated earlier in this document have been met, and each author believes that the manuscript represents honest work.

Corresponding author

Correspondence to Shatavisa Mukherjee.

Ethics declarations

Conflict of interest

Authors declare no conflicts of interest.

Authorship requirement

Authorship required one or more of the following: original conceptualisation, literature study, data extraction and analysis, manuscript preparation and editing.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Samajdar, S.S., Joshi, S.R., Mukherjee, S. et al. Effectiveness and safety of Glargine U-100 and detemir insulin in hyperglycemic pregnancy: a record-based observational study. Int J Diabetes Dev Ctries (2023). https://doi.org/10.1007/s13410-023-01269-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s13410-023-01269-2

Keywords

Search

Navigation